$LUMO
Lumos Pharma Inc Stock $lumo

$lumo Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000112623421000034 Filed on March 09, 2021

Income Statement

Concept	2020 Q4	2019 Q4	2019
Revenue	$0.00	$433.0K	$0.00
YoY Change	-100.0%	114.36%	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.600M	$1.100M	$20.60M
YoY Change	318.18%	-79.63%	-27.46%
% of Gross Profit
Research & Development	$2.500M	$2.400M	$5.669M
YoY Change	4.17%	-57.89%	-87.59%
% of Gross Profit
Depreciation & Amortization	$200.0K	$1.600M	$37.00K
YoY Change	-87.5%	700.0%	-96.77%
% of Gross Profit
Operating Expenses	$7.100M	$3.500M	$9.816M
YoY Change	102.86%	-68.47%	-86.9%
Operating Profit		-$8.689M	-$9.816M
YoY Change		-20.62%	-84.28%
Interest Expense	$0.00	$400.0K	$50.00K
YoY Change	-100.0%	-20.0%	-3.85%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	$111.0K
YoY Change		-100.0%	-94.08%
Pretax Income	-$7.100M	-$8.300M	-$9.705M
YoY Change	-14.46%	-20.95%	-83.98%
Income Tax	-$14.00M	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.400M	-$8.271M	-$9.705M
YoY Change	-70.98%	-21.74%	-81.89%
Net Earnings / Revenue		-1910.16%
Basic Earnings Per Share		-$0.22
Diluted Earnings Per Share	-$289.2K	-$2.024M	-$10.49M
COMMON SHARES
Basic Shares Outstanding	8.297M shares	37.31M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q4	2019 Q4	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$98.70M	$5.000M	$5.000M
YoY Change	1874.0%	-95.86%	-95.86%
Cash & Equivalents	$98.70M	$5.000M	$5.000M
Short-Term Investments
Other Short-Term Assets	$3.500M	$100.0K	$100.0K
YoY Change	3400.0%	-98.18%	-98.18%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$26.15M	$35.00K
Total Short-Term Assets	$128.4M	$5.069M	$5.100M
YoY Change	2434.01%	-96.01%	-95.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$335.0K	$84.00K	$500.0K
YoY Change	298.81%	-97.75%	-86.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$0.00	$0.00
YoY Change
Total Long-Term Assets	$584.0K	$457.0K	$400.0K
YoY Change	27.79%	-88.18%	-89.47%
TOTAL ASSETS
Total Short-Term Assets	$128.4M	$5.069M	$5.100M
Total Long-Term Assets	$584.0K	$457.0K	$400.0K
Total Assets	$129.0M	$5.526M	$5.500M
YoY Change	2235.02%	-95.78%	-95.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$244.0K	$365.0K	$400.0K
YoY Change	-33.15%	-34.23%	-33.33%
Accrued Expenses	$5.898M	$709.0K	$900.0K
YoY Change	731.88%	-91.29%	-88.89%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$6.461M	$1.263M	$1.300M
YoY Change	411.56%	-85.72%	-85.23%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.000M	$200.0K	$200.0K
YoY Change	2900.0%	-97.1%	-97.1%
Total Long-Term Liabilities	$6.000M	$191.0K	$200.0K
YoY Change	3041.36%	-97.25%	-97.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.461M	$1.263M	$1.300M
Total Long-Term Liabilities	$6.000M	$191.0K	$200.0K
Total Liabilities	$12.46M	$1.454M	$1.500M
YoY Change	757.02%	-90.8%	-90.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$65.99M	-$59.68M
YoY Change	10.58%	-79.49%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00	$0.00
YoY Change		-100.0%
Treasury Stock Shares	0.000 shares	176.6K shares
Shareholders Equity	$116.6M	-$59.46M	$4.100M
YoY Change
Total Liabilities & Shareholders Equity	$129.0M	$5.526M	$5.500M
YoY Change	2235.02%	-95.78%	-95.8%

Cashflow Statement

Concept	2020 Q4	2019 Q4	2019
OPERATING ACTIVITIES
Net Income	-$2.400M	-$8.271M	-$9.705M
YoY Change	-70.98%	-21.74%	-81.89%
Depreciation, Depletion And Amortization	$200.0K	$1.600M	$37.00K
YoY Change	-87.5%	700.0%	-96.77%
Cash From Operating Activities	-$7.000M	-$23.80M	-$9.090M
YoY Change	-70.59%	1730.77%	-76.04%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$100.0K	$100.0K
YoY Change	-100.0%		0.0%
Cash From Investing Activities	-$100.0K	$100.0K	-$2.000K
YoY Change	-200.0%		-101.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$14.00K
YoY Change			-94.91%
Debt Paid & Issued, Net			$61.00K
YoY Change			-63.47%
Cash From Financing Activities	100.0K	-100.0K	$22.00K
YoY Change	-200.0%		-114.86%
NET CHANGE
Cash From Operating Activities	-7.000M	-23.80M	-$9.090M
Cash From Investing Activities	-100.0K	100.0K	-$2.000K
Cash From Financing Activities	100.0K	-100.0K	$22.00K
Net Change In Cash	-7.000M	-23.80M	-$9.070M
YoY Change	-70.59%	1730.77%	-76.11%
FREE CASH FLOW
Cash From Operating Activities	-$7.000M	-$23.80M	-$9.090M
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$7.000M	-$23.80M	-$9.090M
YoY Change	-70.59%	1730.77%	-76.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Entity File Number EntityFileNumber	001-35342
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001126234
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	us-gaap:LicenseAndServiceMember
CY2020Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1111
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity Registrant Name EntityRegistrantName	LUMOS PHARMA, INC.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	42-1491350
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	4200 Marathon Blvd #200
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Austin
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78756
CY2020	dei	City Area Code CityAreaCode	512
CY2020	dei	Local Phone Number LocalPhoneNumber	215-2630
CY2020	dei	Security12b Title Security12bTitle	Common Stock
CY2020	dei	Trading Symbol TradingSymbol	LUMO
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	94700000	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8325631	shares
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	98679000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4952000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3506000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	82000	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	115000	USD
CY2019Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	26149000	USD
CY2019Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	35000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	128449000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	5069000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	335000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84000	USD
CY2020Q4	nlnk	Operating Lease Rightof Use Asset Noncurrent OperatingLeaseRightofUseAssetNoncurrent	249000	USD
CY2019Q4	nlnk	Operating Lease Rightof Use Asset Noncurrent OperatingLeaseRightofUseAssetNoncurrent	373000	USD
CY2020Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	584000	USD
CY2019Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	457000	USD
CY2020Q4	us-gaap	Assets Assets	129033000	USD
CY2019Q4	us-gaap	Assets Assets	5526000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	244000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	365000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5898000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	709000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	319000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	189000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6461000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1263000	USD
CY2020Q4	nlnk	Deferred Government Grants Obligations Noncurrent DeferredGovernmentGrantsObligationsNoncurrent	6000000	USD
CY2019Q4	nlnk	Deferred Government Grants Obligations Noncurrent DeferredGovernmentGrantsObligationsNoncurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	191000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6000000	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	191000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	12461000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	1454000	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2019Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	36000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8305269	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8305269	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1177933	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1177933	shares
CY2020Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	83000	USD
CY2019Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	12000	USD
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	176623	shares
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	182480000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	202000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65991000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59677000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	116572000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-59463000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	129033000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5526000	USD
CY2020	us-gaap	Revenues Revenues	168000	USD
CY2019	us-gaap	Revenues Revenues	0	USD
CY2020	us-gaap	Revenues Revenues	168000	USD
CY2019	us-gaap	Revenues Revenues	0	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9206000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5669000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17265000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4147000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	26471000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	9816000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-26303000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-9816000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6467000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	37000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	200000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	74000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6667000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	111000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19636000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9705000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-13973000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5663000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-9705000	USD
CY2020	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	651000	USD
CY2019	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	3040000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6314000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12745000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.93
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-9.79
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6777932	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1302390	shares
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-46919000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	179000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	22000	USD
CY2019	nlnk	Preferred Stock Accretion Of Preferred Dividend Prior To Acquisition PreferredStockAccretionOfPreferredDividendPriorToAcquisition	3040000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-9705000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-59463000	USD
CY2020	nlnk	Preferred Stock Accretion Of Preferred Dividend Prior To Acquisition PreferredStockAccretionOfPreferredDividendPriorToAcquisition	651000	USD
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	116949000	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	64186000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1074000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	116000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	24000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5663000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	116572000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5663000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-9705000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1074000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	179000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	584000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	37000	USD
CY2020	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	6300000	USD
CY2019	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	0	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	426000	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-9500000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	731000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-85000	USD
CY2020	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-309000	USD
CY2019	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3196000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	314000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22997000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9090000	USD
CY2020	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	84179000	USD
CY2019	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	0	USD
CY2020	us-gaap	Proceeds From Divestiture Of Businesses And Interests In Affiliates ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates	32500000	USD
CY2019	us-gaap	Proceeds From Divestiture Of Businesses And Interests In Affiliates ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates	0	USD
CY2020	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	30000	USD
CY2019	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	2000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	116649000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	140000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	22000	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	38000	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	27000	USD
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	75000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	93727000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9070000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4952000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14022000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98679000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4952000	USD
CY2020	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	4473000	USD
CY2019	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	0	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	8000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	64186000	USD
CY2019	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	116949000	USD
CY2019	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2020	nlnk	Settlement Of Liability Related To Priority Review Voucher SettlementOfLiabilityRelatedToPriorityReviewVoucher	35720000	USD
CY2019	nlnk	Settlement Of Liability Related To Priority Review Voucher SettlementOfLiabilityRelatedToPriorityReviewVoucher	0	USD
CY2020	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="text-align:justify;text-indent:22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Organization and Nature of operations</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this Annual Report to “us,” “we,” “our,” the “Company,” or “Lumos” are to Lumos Pharma, Inc. and its wholly-owned subsidiaries. With our principal executive offices located in Austin, Texas and additional executive and administrative offices located in Ames, Iowa, we are engaged in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advancing our clinical program and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">focused on</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">identifying, acquiring, developing, and commercialization of novel products and new therapies for people with rare diseases on a global level</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for which there is currently a significant unmet need for safe and effective therapies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Market (“Nasdaq”) and trades under</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the ticker symbol “LUMO.”</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Company </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entered into a business combination (the “Merger”) between</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company, formerly known as NewLink Genetics Corporation (“NewLink”), Cyclone Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of NewLink, and Lumos Pharma, Inc., which has since been renamed “Lumos Pharma Sub, Inc.” (“Private Lumos”). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger closed on March 18, 2020, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merger Sub merged with and into Private Lumos, with Private Lumos surviving as a wholly-owned subsidiary of the Company. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the Merger, the shares of NewLink common stock were adjusted with a reverse split ratio of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1‑for‑9.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the terms of the Merger, Private Lumos stockholders received an aggregate of 4,146,398 shares </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of NewLink common stock (after giving effect to the reverse split)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each share of outstanding common stock, Series A Preferred Stock and Series B Preferred Stock of Private Lumos converted at an exchange ratio of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1308319305, 0.0873621142 and 0.1996348626</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Immediately following the reverse stock split and the completion of the Merger, there were 8,292,803 shares of the Company’s common stock outstanding</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of which approximately 50% was held by each of Private Lumos and NewLink security holders.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger was accounted for as a reverse asset acquisition. Private Lumos was deemed to be the accounting acquirer for accounting purposes and NewLink </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> accounting acquiree. Accordingly, for accounting purposes: (i) the assets acquired and liabilities assumed were recorded based on their estimated fair values on the Merger date,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) the reported historical operating results of the combined company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prior</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Merger will be those of Private Lumos and not of NewLink after retroactively giving effect to the common stock exchange ratio, reverse stock split and change in par value for all periods presented, and (iii) for periods prior to the transaction, shareholders’ authorized capital of the combined company is presented based on the historical authorized capital of NewLink.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the consummation of the Merger, the combined company has focused its efforts on the development of Private Lumos’ sole product candidate, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">secretagogue </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ibutamoren (“LUM-201”), a potential oral therapy for pediatric growth hormone deficiency (“PGHD”) and other rare endocrine disorders.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Risks</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically devoted substantially all of its efforts toward research and development and has never earned revenue from commercial sales of its products. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities. However, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company believes that its existing cash and cash equivalents </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of approximately $98.7 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December 31, 2020 and the second and final installment of $26.0 million received on January 11, 2021 related to sale of priority review voucher (“PRV”) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be sufficient to allow the Company to fund its operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through read out of the Phase 2b Trial for a subset of patients with PGHD indication under its LUM-201 product candidate and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for at least 12 months from the filing date of this Annual Report. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If available liquidity becomes insufficient to meet the Company’s obligations as they come due, our f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uture operations will be reliant on additional equity or financing arrangements. There can be no assurances that, in the event that the Company requires additional financing, such financing will be </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on terms which are favorable to the Company, or at all. If the Company is unable to raise additional funding to meet its working capital needs in the future, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic caused by an outbreak of a novel strain of coronavirus, SARS-CoV-2, which causes COVID-19 (“COVID-19”), has resulted, and is likely to continue to result, in significant national and global economic disruption and may adversely affect the Company’s operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is actively monitoring the potential impact of COVID-19, if any, on </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the carrying value of certain assets and its continued operations. To date, we have experienced limited delays related to clinical trials as clinical sites adapt their procedures to caring for patients during a pandemic, however, we have not incurred impairment of any assets as a result of COVID-19. The extent to which these events may impact the Company’s business, clinical development, regulatory efforts, and the value of its common stock, will depend on future developments, which are highly uncertain and cannot be predicted at this time. The duration and intensity of these impacts and resulting disruption to the Company’s operations is uncertain and the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company will continue to evaluate the impact that these events could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2021.</span>
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8292803	shares
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98700000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’s financial statements and accompanying notes. Significant management estimates that affect the reported amounts of assets and liabilities include useful lives of property and equipment, stock-based compensation, accruals for clinical trials and deferred tax assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that the estimates and assumptions used in preparation of our consolidated financial statements </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on our knowledge of current events and actions that we may undertake in the future</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are appropriate, actual results could differ from those estimates, and any such differences may be material.</span></div>
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	98700000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5000000.0	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	426000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P6M
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high quality securities such as money market funds.
CY2020Q1	nlnk	Number Of Board Of Directors NumberOfBoardOfDirectors	3	director
CY2020Q2	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	426000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	278000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	278000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5000	USD
CY2020Q4	nlnk	Lessee Operating Lease Liability Unamortized Lease Incentive LesseeOperatingLeaseLiabilityUnamortizedLeaseIncentive	46000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	319000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1074000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	179000	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3500000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y1M6D
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	100000	USD
CY2020Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-14000000.0	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2019Q4	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-4473000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-7980000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1520000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-13973000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q4	nlnk	Cares Act Operating Loss Carry Back Before Tax CARESActOperatingLossCarryBackBeforeTax	4500000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	9500000	USD
CY2020Q4	nlnk	Cares Act Operating Loss Carry Back Before Tax CARESActOperatingLossCarryBackBeforeTax	4500000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27441000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8768000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	34238000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	624000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	41399000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	109000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	361000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	25000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	0	USD
CY2020Q4	nlnk	Deferred Tax Assets Leasehold Improvements And Equipment DeferredTaxAssetsLeaseholdImprovementsAndEquipment	1648000	USD
CY2019Q4	nlnk	Deferred Tax Assets Leasehold Improvements And Equipment DeferredTaxAssetsLeaseholdImprovementsAndEquipment	0	USD
CY2020Q4	nlnk	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	0	USD
CY2019Q4	nlnk	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	733000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	90000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	105845000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	9591000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	105272000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9591000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	573000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	573000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	95700000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1800000	USD
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	104400000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.5050
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	1.7731
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	0
CY2020	nlnk	Effective Income Tax Rate Reconciliation Federal Operating Loss Carryback EffectiveIncomeTaxRateReconciliationFederalOperatingLossCarryback	0.2278
CY2019	nlnk	Effective Income Tax Rate Reconciliation Federal Operating Loss Carryback EffectiveIncomeTaxRateReconciliationFederalOperatingLossCarryback	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	2.0325
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.1834
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0282
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0266
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.7116
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	700000	USD
CY2019Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	USD
CY2020Q4	nlnk	Common Stock Number Of Votes Each Share Is Entitled To CommonStockNumberOfVotesEachShareIsEntitledTo	1	vote
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	nlnk	Common Stock Number Of Votes Each Share Is Entitled To CommonStockNumberOfVotesEachShareIsEntitledTo	1	vote
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q3	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	176623	shares
CY2019Q3	nlnk	Number Of Stockholders NumberOfStockholders	2	stockholder
CY2019Q3	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	20	USD
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5663000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-9705000	USD
CY2020	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	651000	USD
CY2019	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	3040000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6314000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12745000	USD
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6777932	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1302390	shares
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.93
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-9.79
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1032699	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	206560	shares
CY2019Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.60
CY2020Q1	us-gaap	Restructuring Charges RestructuringCharges	5600000	USD
CY2019Q4	us-gaap	Restructuring Reserve RestructuringReserve	4700000	USD
CY2020	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2020	us-gaap	Payments For Restructuring PaymentsForRestructuring	4641000	USD
CY2020Q4	us-gaap	Restructuring Reserve RestructuringReserve	59000	USD

Files In Submission

Name	View Source	Status
0001126234-21-000034-index-headers.html	Edgar Link	pending
0001126234-21-000034-index.html	Edgar Link	pending
0001126234-21-000034.txt	Edgar Link	pending
0001126234-21-000034-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image1.jpg	Edgar Link	pending
lumo-20201231x10kxex311.htm	Edgar Link	pending
lumo-20201231x10kxex312.htm	Edgar Link	pending
lumo-20201231x10kxex321.htm	Edgar Link	pending
lumo-20201231x10xkxex1020.htm	Edgar Link	pending
lumo-20201231x10xkxex211.htm	Edgar Link	pending
lumo-20201231x10xkxex231.htm	Edgar Link	pending
lumo-20201231x10xkxex31.htm	Edgar Link	pending
lumo-20201231x10xkxex42.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nlnk-20201231.htm	Edgar Link	pending
nlnk-20201231.xsd	Edgar Link	pending
nlnk-20201231_cal.xml	Edgar Link	unprocessable
nlnk-20201231_def.xml	Edgar Link	unprocessable
nlnk-20201231_g1.jpg	Edgar Link	pending
nlnk-20201231_g2.jpg	Edgar Link	pending
nlnk-20201231_g3.jpg	Edgar Link	pending
nlnk-20201231_g4.jpg	Edgar Link	pending
nlnk-20201231_htm.xml	Edgar Link	completed
nlnk-20201231_lab.xml	Edgar Link	unprocessable
nlnk-20201231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUMO
Lumos Pharma Inc Stock $lumo

2020 Q4 Form 10-K Financial Statement

#000112623421000034 Filed on March 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO Lumos Pharma Inc Stock $lumo

2020 Q4 Form 10-K Financial Statement

#000112623421000034 Filed on March 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO
Lumos Pharma Inc Stock $lumo